655 related articles for article (PubMed ID: 10955327)
1. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
Eisen GM; Goldstein JL; Hanna DB; Rublee DA
Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
[TBL] [Abstract][Full Text] [Related]
3. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Goldstein JL; Zhao SZ; Burke TA; Palmer R; von Allmen H; Henderson SC
Am J Gastroenterol; 2003 Dec; 98(12):2627-34. PubMed ID: 14687808
[TBL] [Abstract][Full Text] [Related]
4. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
5. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
6. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
9. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
[TBL] [Abstract][Full Text] [Related]
11. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
14. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.
McKenna F; Arguelles L; Burke T; Lefkowith J; Geis GS
Clin Exp Rheumatol; 2002; 20(1):35-43. PubMed ID: 11892706
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
16. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
17. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
18. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Bensen WG
J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
Kivitz A; Eisen G; Zhao WW; Bevirt T; Recker DP
J Fam Pract; 2002 Jun; 51(6):530-7. PubMed ID: 12100776
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]